An Introduction to Macular Degeneration
The treatment landscape for macular degeneration is evolving with many new potential therapies under investigation. The standard of care in wet age-related macular degeneration (AMD) was revolutionised in 2005 with the introduction of anti-VEGF therapies, and current research into port delivery systems and drug combinations aim to provide longer-lasting treatments. Dry AMD is a challenging condition with no current treatment option, but research into stem cell therapies and drugs that slow the progression of geographic atrophy show much promise.
Browse the content below, to see leading experts discuss the latest data in video interviews and short articles from our conference hub. You can also view the selection of peer-reviewed articles from our journals. If you’re looking to learn more about the impact of these developments on patient outcomes, our educational activities are a great resource.
Our supporting partners do not constitute an endorsement of the content on this page.
Macular Degeneration Content
Kyoko Ohno-Matsui, EURETINA 2021: Advantages and Limitations of a Deep Learning Algorithm
We were delighted to speak with Kyoko Ohno-Matsui (Tokyo Medical and Dental University, Tokyo, Japan) about the potential advantages and limitations of a deep learning algorithm for automated detection of myopic maculopathy and pathologic myopia in fundus images, and the challenges in developing this algorithm. Questions What are the potential advantages and limitations of a […]
Kyoko Ohno-Matsui, EURETINA 2021: Results of a Study Evaluating a Deep Learning Algorithm
It was a pleasure to catch up with Kyoko Ohno-Matsui (Tokyo Medical and Dental University, Tokyo, Japan), who discussed the results of her study evaluating a deep learning algorithm for automated detection of myopic maculopathy and pathologic myopia in fundus images. Questions What were the methodology and outcome measures of your study evaluating a deep […]
Faricimab: An Emerging Therapy for the Treatment of Neovascular Age-related Macular Degeneration
touchREVIEWS in Ophthalmology. 2021; 15(1):23–5 DOI: https://doi.org/10.17925/OPHT.2021.15.1.23
Neovascular age-related macular degeneration (nAMD) is characterized by the growth of abnormal blood vessels extending through Bruchs membrane in the macular region.1 This macular neovascularization (MNV) can be classified based on localization as either type 1, type 2, type 3 or mixed lesions.2 In type 1 MNV (also known as occult lesions), the neovascularization arises […]
Carl Regillo, Hawaiian Eye and Retina 2021: Geographic Atrophy – Current Therapeutic Approaches and Future Prospects
It was a pleasure to catch up with Carl Regillo (Wills Eye Hospital, Philadelphia, PA, USA), who talked us through the therapeutic approaches currently in clinical trial investigation for the treatment of geographic atrophy, and his views on exciting future prospects for treatment. Questions Could you give us a brief overview of the therapeutic approaches […]
Carl Regillo, Hawaiian Eye and Retina 2021: Geographic Atrophy – Incidence and Prognosis
We enjoyed speaking to Carl Regillo (Wills Eye Hospital, Philadelphia, PA, USA) about incidence and prognosis of geographic atrophy, and advances in understanding of genetics and pathophysiology of dry AMD. Questions Could you give us a brief overview of geographic atrophy, its incidence and prognosis? (00:17) Why have we failed to achieve the same breakthroughs […]
HAWK and HARRIER: Ninety-Six-Week Outcomes from the Phase III Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration
The burden of neovascular age-related macular degeneration (nAMD) remains high in real world clinical practice, and new treatments are needed to improve outcomes and reduce the amount of clinic visits.
- Describe the design and outcomes of the HAWK and HARRIER trials
- Discuss how the results of the HAWK and HARRIER trials inform daily clinical practice
- Summarize the impact of brolucizumab on the management of patients with nAMD
New Age-related Macular Degeneration Injectables
European Ophthalmic Review. 2020;14(1):17–20 DOI: https://doi.org/10.17925/EOR.2020.14.1.17
Modern treatments for wet age-related macular degeneration (wAMD) have progressed tremendously in the last decade, with the rise of anti-vascular endothelial growth factor (anti-VEGF) intravitreal injections as the standard-of-care. Both aflibercept (Eylea®, Regeneron, Tarrytown, NY, USA) and ranibizumab (Lucentis®, Genentech, San Francisco, CA, USA) have become the gold standard for anti-VEGF agents. Initially, patients with […]
Assaf Hilely, ESCRS 2020 – Non-neovascular Age-related Macular Degeneration with Subretinal Fluid
We caught up with Editorial Board member Dr Assaf Hilely (Tel Aviv Medical Center, Tel Aviv, Israel), who talked us through his recent study of non-neovascular age-related macular degeneration with subretinal fluid. Questions What prognostic factors are currently used to guide treatment when initiating anti-vascular endothelial growth factor treatment for patients with age-related macular degeneration […]
Anat Loewenstein, EURETINA 2020 – The Importance of Home Monitoring
It was a pleasure to catch up with our Editorial Board member, Prof. Anat Loewenstein (Tel Aviv Medical Center, Israel), who talked to us about the importance of home monitoring in wet age-related macular degeneration. How has the COVID-19 pandemic affected the management of patients with wet age-related macular degeneration (AMD)? (0:10) How can home […]
Journal articles and more to your inbox
Get the latest clinical insights from touchOPHTHALMOLOGYSign me up!